Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;2(12):970-5.
doi: 10.18632/oncotarget.398.

CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients

Daniel Baumhoer  1 , Mareike Elsner, Jan Smida, Stephanie Zillmer, Sandra Rauser, Cédrik Schoene, Benjamin Balluff, Stefan Bielack, Gernot Jundt, Axel Walch, Michaela Nathrath
Affiliations

CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients

Daniel Baumhoer et al. Oncotarget. 2011 Dec.

Abstract

Predicting the clinical course of osteosarcoma patients is a crucial prerequisite for a better treatment stratification in these highly aggressive neoplasms of bone. In search of new and reliable biomarkers we recently identified cysteine-rich intestinal protein 1 (CRIP1) to have significant prognostic impact in gastric cancer and therefore decided to investigate its role also in osteosarcoma. For this purpose we analyzed 223 pretherapeutic and well characterized osteosarcoma samples for their immunohistochemical expression of CRIP1 and correlated our findings with clinico-pathological parameters including follow‑up, systemic spread and response to chemotherapy. Interestingly and contrarily to gastric cancer, we found CRIP1 expression more frequently in patients with long‑term survival (10-year survival 73% in positive vs. 54% in negative cases, p = 0.0433) and without metastases (p = 0.0108) indicating a favorable prognostic effect. CRIP1 therefore seems to represent a promising new biomarker in osteosarcoma patients which should be considered for a prospective validation.

PubMed Disclaimer

Conflict of interest statement

We declare that we have no conflict of interest.

Figures

Figure 1
Figure 1. Immunhistochemistry for CRIP1
Absent (A) or focal (< 50% positive tumor cells) immunoreactivity was considered negative. Strong and constant staining (B, C) or immunoreactivity in more than 50% of tumor cells (D) was regarded CRIP1 positive. All pictures x200.
Figure 2
Figure 2. Kaplan-Meier curves comparing 10-year survival of osteosarcomas with and without CRIP1 expression
See this image and copyright information in PMC

References

    1. Raymond AK, Ayala AG, Knuutila S. Conventional osteosarcoma. In: Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press; Lyon, France: 2002. pp. 264–270.
    1. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–790. - PubMed
    1. Kong C, Hansen MF. Biomarkers in osteosarcoma. Expert Opin Med Diagn. 2009;3:13–23. - PMC - PubMed
    1. Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80. J Cancer Res Clin Oncol. 1983;106(Suppl):21–24. - PubMed
    1. Smida J, Baumhoer D, Rosemann M, Walch A, Bielack S, Poremba C, Remberger K, Korsching E, Scheurlen W, Dierkes C, Burdach S, Jundt G, Atkinson MJ, Nathrath M. Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin Cancer Res. 2010;16:4256–4267. - PubMed

Publication types

MeSH terms